This is a working overview of GHSR-1a, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-12-25. Anything still debated is marked as such rather than presented as settled.
At the molecular level, ipamorelin acts as an agonist at the growth hormone secretagogue receptor, also called the ghrelin receptor or GHS-R1a. Binding to this receptor on pituitary somatotroph cells triggers a signaling cascade that leads to growth hormone release. The effect is mediated through phospholipase C and calcium mobilization rather than through the cyclic AMP pathway used by growth hormone releasing hormone. The two pathways are complementary, and combined stimulation produces a larger response than either alone.
Compared with other secretagogues such as GHRP-2, GHRP-6, and hexarelin, ipamorelin is described as more selective. Published animal work reports little or no increase in adrenocorticotropic hormone, cortisol, or prolactin at doses that release growth hormone. This selectivity is the property most often cited in the research literature. Whether the same profile holds across species and dosing schedules remains an open question, since human data are limited and come largely from small studies.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue family. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, and its molecular mass is approximately 711.9 daltons. The compound was described in the late 1990s by researchers seeking molecules that release growth hormone with fewer side effects than earlier secretagogues. It is a laboratory and research compound, not an approved medicine in most jurisdictions.
In animal and early human studies, ipamorelin produces pulsatile growth hormone release and a secondary rise in insulin-like growth factor 1. The magnitude and duration of that rise depend on route, sampling schedule, and the baseline endocrine state of the subject. Whether repeated exposure alters the response over time is not firmly settled, since some reports describe stable pulsatility while others note attenuation. Most published data come from small samples, which limits the strength of any general claim about long-term behavior.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue class of compounds. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, a structure that differs from natural ghrelin in length and in the presence of non-natural amino acid residues. Early laboratory work described it as a comparatively selective agent that stimulates growth hormone release with limited effect on other pituitary hormones. The compound is supplied as a lyophilized solid for research use and has no identified natural source in the body.
Activity is mediated mainly through the growth hormone secretagogue receptor, now generally called the ghrelin receptor or GHS-R1a. Binding at this G-protein-coupled receptor triggers phospholipase C signaling, calcium mobilization, and release of growth hormone from pituitary somatotrophs. Reports describe less pronounced stimulation of adrenocorticotropic hormone and prolactin compared with earlier secretagogues such as hexarelin or GHRP-6. Selectivity figures vary between assay systems, so the degree of separation from other secretagogues is an area of ongoing comparison rather than a fixed constant.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic pentapeptide | Growth hormone secretagogue family |
| Molecular mass | Approximately 711.9 Da | Free base, calculated value |
| Receptor target | GHS-R1a, the ghrelin receptor | Agonist activity reported |
| Sequence | Aib-His-D-2-Nal-D-Phe-Lys-NH2 | C-terminal amide |
| Reported selectivity | Little change in ACTH, cortisol, prolactin | Based mainly on animal data |
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue class. It acts as an agonist at the ghrelin receptor, also called the growth hormone secretagogue receptor type 1a. The compound was designed in the 1990s during a search for agents that release growth hormone with fewer off-target hormonal effects than earlier secretagogues. It appears in the research literature under several sequence-based names. Material supplied for laboratory work is normally a lyophilized solid, and it is not marketed as an approved therapeutic in major jurisdictions.
The molecule contains five residues, including alpha-aminoisobutyric acid, D-2-naphthylalanine, and D-phenylalanine, and it ends in a lysine amide. Non-natural and D-configured residues make the chain less susceptible to common peptidases, which helps explain its resistance to rapid breakdown. Its molecular formula is C38H49N9O5, corresponding to a free-base mass near 711.9 daltons. The C-terminal amide removes a negative charge and is a recurring feature in receptor-active peptides of this family. These structural choices are usually discussed as the basis for its selectivity profile.
At the receptor level, ipamorelin binds GHS-R1a and triggers signaling through Gq-coupled pathways. Activation leads to calcium release and downstream effects in pituitary somatotroph cells. These events promote the release of growth hormone into circulation. The response depends on the presence of the receptor and on the physiological state of the animal or tissue studied. Because the receptor is also found in other tissues, effects beyond the pituitary have been examined in laboratory models, though the extent of those effects remains an area of ongoing study.
One distinguishing feature reported in animal studies is selectivity. Ipamorelin stimulated growth hormone release with limited elevation of adrenocorticotropic hormone or cortisol compared with earlier secretagogues such as GHRP-6. This pattern has been described as more selective for the growth hormone axis. The finding comes mainly from preclinical work, and the degree to which it holds across species and doses is not fully settled. Reports also describe effects on gastric motility in animal models, suggesting activity outside the pituitary, though the clinical relevance of this observation is uncertain.
Ipamorelin is a synthetic pentapeptide that acts on the growth hormone secretagogue receptor, also known as the ghrelin receptor. Its sequence contains five amino acid residues, including a non-natural residue that increases stability against enzymatic breakdown. The compound was developed in the 1990s as part of research into small peptides that stimulate pituitary hormone release. Unlike larger protein hormones, it can be produced by solid-phase peptide synthesis and characterized by standard analytical methods.
Structural features distinguish the molecule from earlier secretagogues. An alpha-aminoisobutyric acid residue near the N-terminus and a D-naphthylalanine substitution increase receptor affinity, while C-terminal amidation improves resistance to exopeptidases. These modifications are associated with reduced stimulation of appetite and of the hypothalamic-pituitary-adrenal axis compared with hexarelin or growth hormone releasing peptide-6. Whether the same profile applies at every dose level studied is a matter of ongoing investigation rather than settled consensus.
Ipamorelin is a synthetic pentapeptide that acts as an agonist at the ghrelin receptor, also called the growth hormone secretagogue receptor type 1a. Its sequence incorporates non-natural residues, which slows enzymatic breakdown relative to short native peptides. In laboratory and early clinical work the compound is described as a selective growth hormone secretagogue because it raises growth hormone with comparatively little effect on other pituitary outputs. The degree to which that selectivity holds across species and dosing regimens remains an open question in the published literature.
1852: Ingouville and parts of Graville-l'Eure and Sanvic 1919: all of Graville-Sainte-Honorine 1953: Bleville 1955: all of Sanvic 1971: part of Harfleur (a district of Caucriauville) 1973: Rouelles (with the status of associated commune, 3,184 inhabitants in 2006)
p53, also known as tumor protein p53, TP53, cellular tumor antigen p53 (UniProt name), or transformation-related protein 53 (TRP53) is a regulatory transcription factor protein that is often mutated in human cancers. The p53 proteins (originally thought to be, and often spoken of as, a single protein) are crucial in vertebrates, where they prevent cancer formation. As such, p53 has been described as "the guardian of the genome" because of its role in conserving stability by preventing genome mutation. Hence TP53 is classified as a tumor suppressor gene. The TP53 gene is inactivated in a majority (>50%) of human cancer cases. This can be caused by any various factors, including mutations in the gene, epigenetic events, or interactions with other proteins. This association indicates that the TP53 gene plays a crucial role in preventing cancer formation. TP53 gene encodes proteins that bind to DNA and regulate gene expression to prevent mutations of the genome. In addition to the full-length protein, the human TP53 gene encodes at least 12 protein isoforms. Comparative genomic studies found pathogenic mutations absent in some Neanderthal populations, while modern humans exhibit an expansion of over 1,000 mutated variations. Evidence suggests that the vast majority of these protein-coding variants arose very recently in human history, specifically concentrated within a window of 5,000 to 10,000 years ago.
=== Blocking of L-type calcium channels === Because the presence of calcium in the cytosol is required for muscle contraction, blockers of calcium channels prevent the muscles from building tension. Blockers of the L-type calcium channels, which occur in cardiac and smooth muscles, thus act as smooth muscle relaxants and inhibitors of cardiac contractions. Common blockers of L-type calcium channels are 1,4-dihydropyridines, which are used in treatment of cardiovascular diseases. Because of their activity as a relaxant, they can relax smooth muscles surrounding blood vessels, thus widening them and lowering the blood pressure.
=== 8 April === Three people were killed and eight others were injured in a Russian missile attack on Zaporizhzhia. One person was killed and five others were injured in Russian air strikes in Sumy Oblast. Two people were killed in separate attacks in Chasiv Yar and Poltava. Ukrainian hackers launched a cyberattack on a data center used by the Russian military, energy, and telecommunications industries, which affected 10,000 enterprises including Gazprom and Lukoil. The SBU arrested a former member of the Party of Regions in Sumy Oblast on suspicion of spying for Russia.
== See also == Farkas, Etelka; Buglyó, Péter (2017). "Chapter 8. Lead(II) Complexes of Amino Acids, Peptides, and Other Related Ligands of Biological Interest". In Astrid, S.; Helmut, S.; Sigel, R. K. O. (eds.). Lead: Its Effects on Environment and Health. Metal Ions in Life Sciences. Vol. 17. de Gruyter. pp. 201–240. doi:10.1515/9783110434330-008. PMID 28731301. pp. 228–230 Dunaliella
Sources: en.wikipedia.org
From 1928 to 1932, Albert Szent-Györgyi and Joseph L. Svirbely's Hungarian team, and Charles Glen King's American team, identified the anti-scorbutic factor. Szent-Györgyi isolated hexuronic acid from animal adrenal glands, and suspected it to be the antiscorbutic factor. In late 1931, Szent-Györgyi gave Svirbely the last of his adrenal-derived hexuronic acid with the suggestion that it might be the anti-scorbutic factor. By the spring of 1932, King's laboratory had proven this, but published the result without giving Szent-Györgyi credit for it. This led to a bitter dispute over priority. In 1933, Walter Norman Haworth chemically identified the vitamin as l-hexuronic acid, proving this by synthesis in 1933. Haworth and Szent-Györgyi proposed that L-hexuronic acid be named a-scorbic acid, and chemically l-ascorbic acid, in honor of its activity against scurvy. The term's etymology is from Latin, "a-" meaning away, or off from, while -scorbic is from Medieval Latin scorbuticus (pertaining to scurvy), cognate with Old Norse skyrbjugr, French scorbut, Dutch scheurbuik and Low German scharbock. Partly for this discovery, Szent-Györgyi was awarded the 1937 Nobel Prize in Medicine, and Haworth shared that year's Nobel Prize in Chemistry. In 1957, J. J. Burns showed that some mammals are susceptible to scurvy as their liver does not produce the enzyme l-gulonolactone oxidase, the last of the chain of four enzymes that synthesize vitamin C. American biochemist Irwin Stone was the first to exploit vitamin C for its food preservative properties.
=== Pharmacogenetics === Since amitriptyline is primarily metabolized by CYP2D6 and CYP2C19, genetic variations within the genes coding for these enzymes can affect its metabolism, leading to changes in the concentrations of the drug in the body. Increased concentrations of amitriptyline may increase the risk for side effects, including anticholinergic and nervous system adverse effects, while decreased concentrations may reduce the drug's efficacy. Individuals can be categorized into different types of CYP2D6 or CYP2C19 metabolizers depending on which genetic variations they carry. These metabolizer types include poor, intermediate, extensive, and ultrarapid metabolizers. Most individuals (about 77–92%) are extensive metabolizers, and have "normal" metabolism of amitriptyline. Poor and intermediate metabolizers have reduced metabolism of the drug as compared to extensive metabolizers; patients with these metabolizer types may have an increased probability of experiencing side effects. Ultrarapid metabolizers use amitriptyline much faster than extensive metabolizers; patients with this metabolizer type may have a greater chance of experiencing pharmacological failure. The Clinical Pharmacogenetics Implementation Consortium recommends avoiding amitriptyline in patients who are CYP2D6 ultrarapid or poor metabolizers, due to the risk of a lack of efficacy and side effects, respectively. The consortium also recommends considering an alternative drug not metabolized by CYP2C19 in patients who are CYP2C19 ultrarapid metabolizers.
== Medical uses == In the United States, gemtuzumab ozogamicin is indicated for newly diagnosed CD33-positive acute myeloid leukemia (AML) for adults and children one month and older and for the treatment of relapsed or refractory CD33-positive AML in adults and children two years and older.
Meta's Llama models, which have been described as open-source by Meta, were adopted by U.S. defense contractors like Lockheed Martin and Oracle after unauthorized adaptations by Chinese researchers affiliated with the People's Liberation Army (PLA) came to light. The Open Source Initiative and others have contested Meta's use of the term open-source to describe Llama, due to Llama's license containing an acceptable use policy that prohibits use cases including non-U.S. military use. Chinese researchers used an earlier version of Llama to develop tools like ChatBIT, optimized for military intelligence and decision-making, prompting Meta to expand its partnerships with U.S. contractors to ensure the technology could be used strategically for national security. These applications now include logistics, maintenance, and cybersecurity enhancements.
Depending on the species, an adult earthworm can be from 10 mm (0.39 in) long and 1 mm (0.039 in) wide to 3 m (9.8 ft) long and over 25 mm (0.98 in) wide, but the typical Lumbricus terrestris grows to about 360 mm (14 in) long. Probably the longest worm on confirmed records is Amynthas mekongianus that extends up to 3 m (10 ft) in the mud along the banks of the 4,350 km (2,700 mi) Mekong River in Southeast Asia. From front to back, the basic shape of the earthworm is a cylindrical tube-in-a-tube, divided into a series of segments (called metameres) that compartmentalize the body. Furrows are generally externally visible on the body demarking the segments. Dorsal pores and nephridiopores exude a fluid that moistens and protects the worm's surface, also allowing it to breathe. Except for the mouth and anal segments, each segment carries bristlelike hairs called lateral setae used to anchor parts of the body during movement. Species may have four pairs of setae on each segment or more than eight sometimes forming a complete circle of setae per segment. Special ventral setae are used to anchor mating earthworms by their penetration into the bodies of their mates. Generally, within a species, the number of segments found is consistent across specimens, and individuals are born with the number of segments they will have throughout their lives, growth in size being by enlarging existing segments rather than by adding new ones.
Sources: en.wikipedia.org
In older literature, adenine was sometimes called Vitamin B4, but is no longer considered a vitamin. Due to it being synthesized by the body and not essential to be obtained by diet, it does not meet the definition of vitamin and is no longer part of the Vitamin B complex. However, two B vitamins, niacin and riboflavin, bind with adenine to form the essential cofactors nicotinamide adenine dinucleotide (NAD) and flavin adenine dinucleotide (FAD), respectively. Hermann Emil Fischer was one of the early scientists to study adenine. It was named in 1885 by Albrecht Kossel after Greek ἀδήν aden "gland", in reference to the pancreas, from which Kossel's sample had been extracted. Adenine can be prepared from ammonia and hydrogen cyanide (HCN) in aqueous solution, a process that has implications for the origin of life on Earth. On August 8, 2011, a report, based on NASA studies with meteorites found on Earth, was published suggesting building blocks of DNA and RNA (adenine, guanine and related organic molecules) may have been formed extraterrestrially in outer space. In 2011, physicists reported that adenine has an "unexpectedly variable range of ionization energies along its reaction pathways" which suggested that "understanding experimental data on how adenine survives exposure to UV light is much more complicated than previously thought"; these findings have implications for spectroscopic measurements of heterocyclic compounds, according to one report.
== Career == Upon receiving his Ph.D., Gattuso moved to Australia where he was a postdoctoral researcher at the Australian Institute of Marine Science(1988-1990). In 1990, Gattuso took a position of CNRS research scientist at Centre de Biologie et Écologie Tropicale et Méditerranéenne of the University of Perpignan (1990-1992). He then moved to the Scientific Center of Monaco to launch and lead the Ecophysiology and Biogeochemistry group. In 1998, Gattuso went back to a CNRS joint laboratory at the Villefranche Oceanographic Observatory and moved to the ranks of Research Professor (directeur de recherche). He is also Associate Scientist at the Institute for Sustainable Development and International Relations (IDDRI-SciencesPo, Paris). Gattuso has been visiting professor or scientist at Rutgers University, the National Center for Atmospheric Research and Shantou University. Gattuso is the founding editor-in-chief of Biogeosciences and served or has served in the editorial board of several scientific journals. He founded the Biogeosciences Division of the European Geosciences Union, and has received multiple awards and honors for his research contributions. He led the launch of the Ocean Acidification International Coordination Centre at the International Atomic Energy Agency, co-edited the first book on ocean acidification (Oxford University Press) and contributed to several IPCC products (5th Assessment Report, Special Report on 1.5°C of Warming, and the Special Report on the Ocean and Cryosphere in a Changing Climate).
Various labs jointly conducted thousands of repetitive chromatographic experiments between 1988 and 1993. All group 5 elements and protactinium were extracted from concentrated hydrochloric acid; after mixing with lower concentrations of hydrogen chloride, small amounts of hydrogen fluoride were added to start selective re-extraction. Dubnium showed behavior different from that of tantalum but similar to that of niobium and its pseudohomolog protactinium at concentrations of hydrogen chloride below 12 moles per liter. This similarity to the two elements suggested that the formed complex was either DbOX−4 or [Db(OH)2X4]−. After extraction experiments of dubnium from hydrogen bromide into diisobutyl carbinol (2,6-dimethylheptan-4-ol), a specific extractant for protactinium, with subsequent elutions with the hydrogen chloride/hydrogen fluoride mix as well as hydrogen chloride, dubnium was found to be less prone to extraction than either protactinium or niobium. This was explained as an increasing tendency to form non‐extractable complexes of multiple negative charges. Further experiments in 1992 confirmed the stability of the +5 state: Db(V) was shown to be extractable from cation‐exchange columns with α‐hydroxyisobutyrate, like the group 5 elements and protactinium; Db(III) and Db(IV) were not. In 1998 and 1999, new predictions suggested that dubnium would extract nearly as well as niobium and better than tantalum from halide solutions, which was later confirmed. The first isothermal gas chromatography experiments were performed in 1992 with 262Db (half-life 35 seconds).
=== Intracellular === Obligate intracellular parasites (e.g. Chlamydophila, Ehrlichia, Rickettsia) are only able to grow and replicate inside other cells. Infections due to obligate intracellular bacteria may be asymptomatic, requiring an incubation period. Examples of obligate intracellular bacteria include Rickettsia prowazekii (typhus) and Rickettsia rickettsii, (Rocky Mountain spotted fever). Chlamydia are intracellular parasites. These pathogens can cause pneumonia or urinary tract infection and may be involved in coronary heart disease. Other groups of intracellular bacterial pathogens include Salmonella, Neisseria, Brucella, Mycobacterium, Nocardia, Listeria, Francisella, Legionella, and Yersinia pestis. These can exist intracellularly, but can exist outside host cells.
Sources: en.wikipedia.org
Ipamorelin is a synthetic pentapeptide that stimulates growth hormone release by activating the ghrelin receptor. It is handled as a research tool rather than as a licensed therapeutic product. Its short chain length makes it comparatively simple to synthesize and analyze.
Both bind the same receptor, but ghrelin is a 28-amino-acid hormone with roles in appetite and energy balance. Ipamorelin is a much smaller synthetic peptide selected for growth hormone release with limited effect on appetite signaling in animal models. The full overlap between their effects is not completely mapped.
Most published data come from animal studies and a small number of human trials. Findings on growth hormone release are reasonably consistent, while long-term effects and direct comparisons with other secretagogues remain incompletely studied. Open questions include duration of action across different populations.
It is a synthetic pentapeptide in the growth hormone secretagogue family and acts as an agonist at the ghrelin receptor. It is handled as a laboratory research compound rather than a naturally occurring hormone.